Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26.000
Filtrar
1.
Am Heart J ; 272: 113-115, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38705638

RESUMO

Despite a perceived increase in attention to gender differences in medicine, a comprehensive assessment of gender equality research, particularly in cardiology, remains underexplored. This observational retrospective study, focusing on documents related to "Gender Equality" according to the Sustainable Development Goals, reveals cardiology as a significant area for gender equality research, albeit with a decline in publications post-2018. The analysis highlighted a concentrated effort in the United States and a considerable impact gap between gender-focused and general cardiology research. The global academic community must intensify research into gender disparities, which is essential for achieving professional gender equality and addressing the burden of cardiovascular diseases.


Assuntos
Pesquisa Biomédica , Cardiologia , Equidade de Gênero , Humanos , Estudos Retrospectivos , Feminino , Masculino , Estados Unidos , Sexismo
2.
13.
Dtsch Med Wochenschr ; 149(12): 719-723, 2024 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-38781996

RESUMO

The emerging field of cardio-oncology addresses the critical need for specialized cardiovascular care in cancer patients, given the overlapping risk factors and potential cardiovascular complications of oncological therapies. In collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the European Society of Cardiology (ESC), the first cardio-oncology guideline was developed and published in 2022. This guideline comprises 272 recommendations covering risk stratification before therapy initiation, monitoring during oncological treatment, and the diagnosis and treatment of therapy-associated cardiovascular side effects.A significant innovation in this guideline is the comprehensive risk stratification approach, which categorizes patients into low, moderate, and high-risk groups based on therapy-specific factors. This allows for tailored cardiovascular care during therapy, with varying frequencies of follow-up examinations depending on the patient's risk level. Notably, the guideline emphasizes the importance of interdisciplinary collaboration between oncologists and cardiologists to optimize patient outcomes.Overall, the cardio-oncology guideline represents a significant advancement in addressing the complex cardiovascular needs of cancer patients. Its comprehensive recommendations and emphasis on interdisciplinary care underscore the importance of optimizing cardiovascular health throughout the oncological treatment journey.This review provides an overview of the guidelines and updates on the risk stratification and therapy of patients with immune checkpoint inhibitor-associated myocarditis (ICIM), as well as the role of statins in protecting against anthracycline-associated cardiotoxicity.


Assuntos
Doenças Cardiovasculares , Neoplasias , Humanos , Neoplasias/complicações , Neoplasias/terapia , Doenças Cardiovasculares/prevenção & controle , Doenças Cardiovasculares/etiologia , Oncologia , Guias de Prática Clínica como Assunto , Cardiotoxicidade/prevenção & controle , Cardiotoxicidade/etiologia , Cardiologia/normas , Medição de Risco , Fatores de Risco , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Cardio-Oncologia
14.
15.
J Am Coll Cardiol ; 83(21): 2128-2129, 2024 May 28.
Artigo em Inglês | MEDLINE | ID: mdl-38777514
16.
Ther Umsch ; 81(2): 60-66, 2024 Apr.
Artigo em Alemão | MEDLINE | ID: mdl-38780212

RESUMO

INTRODUCTION: The new 2023 European Society of Cardiology (ESC) Guidelines for the management of cardiomyopathies addresses all cardiomyopathies in a single document for the first time. The focus is on a phenotype-oriented diagnostic approach, multimodal imaging and genetic testing to establish the most accurate diagnosis possible. Additionally, new recommendations for risk stratification for sudden cardiac death in various cardiomyopathy phenotypes are provided. MRI and genetic testing have significantly gained importance in this context. Recommendations for comprehensive clinical and genetic cascade screening in relatives of individuals with cardiomyopathies have been revised. This article presents the most important innovations of these guidelines in a practice-oriented approach.


Assuntos
Cardiomiopatias , Testes Genéticos , Humanos , Cardiomiopatias/terapia , Cardiomiopatias/diagnóstico , Cardiomiopatias/genética , Guias de Prática Clínica como Assunto , Morte Súbita Cardíaca/prevenção & controle , Morte Súbita Cardíaca/etiologia , Predisposição Genética para Doença/genética , Cardiologia
17.
BMJ Open ; 14(5): e081118, 2024 May 07.
Artigo em Inglês | MEDLINE | ID: mdl-38719297

RESUMO

OBJECTIVE: To characterise sex and gender-based analysis (SGBA) and diversity metric reporting, representation of female/women participants in acute care trials and temporal changes in reporting before and after publication of the 2016 Sex and Gender Equity in Research guideline. DESIGN: Systematic review. DATA SOURCES: We searched MEDLINE for trials published in five leading medical journals in 2014, 2018 and 2020. STUDY SELECTION: Trials that enrolled acutely ill adults, compared two or more interventions and reported at least one clinical outcome. DATA ABSTRACTION AND SYNTHESIS: 4 reviewers screened citations and 22 reviewers abstracted data, in duplicate. We compared reporting differences between intensive care unit (ICU) and cardiology trials. RESULTS: We included 88 trials (75 (85.2%) ICU and 13 (14.8%) cardiology) (n=111 428; 38 140 (34.2%) females/women). Of 23 (26.1%) trials that reported an SGBA, most used a forest plot (22 (95.7%)), were prespecified (21 (91.3%)) and reported a sex-by-intervention interaction with a significance test (19 (82.6%)). Discordant sex and gender terminology were found between headings and subheadings within baseline characteristics tables (17/32 (53.1%)) and between baseline characteristics tables and SGBA (4/23 (17.4%)). Only 25 acute care trials (28.4%) reported race or ethnicity. Participants were predominantly white (78.8%) and male/men (65.8%). No trial reported gendered-social factors. SGBA reporting and female/women representation did not improve temporally. Compared with ICU trials, cardiology trials reported significantly more SGBA (15/75 (20%) vs 8/13 (61.5%) p=0.005). CONCLUSIONS: Acute care trials in leading medical journals infrequently included SGBA, female/women and non-white trial participants, reported race or ethnicity and never reported gender-related factors. Substantial opportunity exists to improve SGBA and diversity metric reporting and recruitment of female/women participants in acute care trials. PROSPERO REGISTRATION NUMBER: CRD42022282565.


Assuntos
Cuidados Críticos , Humanos , Feminino , Masculino , Cuidados Críticos/estatística & dados numéricos , Publicações Periódicas como Assunto/estatística & dados numéricos , Fatores Sexuais , Fator de Impacto de Revistas , Ensaios Clínicos como Assunto , Equidade de Gênero , Cardiologia
18.
Clin Cardiol ; 47(5): e24284, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38766996

RESUMO

BACKGROUND: The 2023 Multisociety Guideline for the Management of Chronic Coronary Disease (CCD) updates recommendations for CCD, formerly known as "stable ischemic heart disease." This condition encompasses a spectrum of coronary vascular pathologies from subclinical to clinical ischemic heart disease. HYPOTHESIS: The new "ABC" mnemonic offers clinicians a streamlined framework for applying Class One Recommendations (COR1) and integrating recent updates into CCD management. METHODS: A critical analysis of the 2023 CCD guidelines was conducted, with this review highlighting key elements. RESULTS: The review outlines crucial changes, including novel recommendations supported by current clinical evidence. The focus is on these developments, clarifying their importance for day-to-day clinical practice. CONCLUSIONS: The review encourages a synergistic approach between primary healthcare providers and cardiologists to develop comprehensive strategies for lifestyle modification and medication therapy in CCD care. Furthermore, it suggests that utilizing comprehensive risk assessment tools can refine medical decision-making, ultimately enhancing patient care and clinical outcomes.


Assuntos
Cardiologia , Guias de Prática Clínica como Assunto , Humanos , Cardiologia/normas , Doença Crônica , Doença das Coronárias/terapia , Doença das Coronárias/diagnóstico , Gerenciamento Clínico , Medição de Risco , Sociedades Médicas , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...